| Heading: |
Glioblastoma: Immunotherapy |
| Question ID: |
1794619 |
| UIN: |
45873 |
| House: |
Commons |
| Date tabled: |
2025-04-17 |
| Asking Member ID: |
4777 |
| Asking Member display name: |
Sarah Owen
|
| Asking Member handle: |
|
| Asking Member Twitter reference: |
Sarah Owen
|
| Member interest: |
true |
| Question text: |
To ask the Secretary of State for Health and Social Care, whether his Department plans to work with the National Institute for Health and Care Excellence to expedite market access to the personalised immunotherapy developed to treat the malignant brain tu |
| Is named day: |
false |
| Date of holding answer: |
|
| Date answered: |
2025-04-28 |
| Date answer corrected: |
|
| Is holding answer: |
false |
| Is correcting answer: |
false |
| Answering Member ID: |
4444 |
| Answering Member display name: |
Karin Smyth
|
| Answering Member handle: |
karinsmyth
|
| Answering Member Twitter reference: |
@karinsmyth
|
| Correcting Member ID: |
|
| Correcting Member display name: |
|
| Correcting Member handle: |
|
| Correcting Member Twitter reference: |
|
| Answer text: |
DCVax-L has not yet been licensed by the Medicines and Healthcare products Regulatory Agency (MHRA) for use in the United Kingdom. The manufacturer has confirmed that it has submitted an application, and it is fully engaged with the Marketing Authorisatio... |
| Original answer text: |
|
| Comparable answer text: |
|
| Answering body ID: |
17 |
| Answering body name: |
Department of Health and Social Care |
| Tweeted: |
true |